

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that, Shijiazhuang No.4 Pharmaceutical Company Limited (a wholly owned subsidiary of the Company in China) has obtained approval from the National Medical Products Administration of China for drug clinical trials for NP-01 tablet, which agreed to launch the clinical trials for advanced solid tumors such as in gastric cancer, lung cancer and liver cancer.

As stated in the Company’s announcement dated 15 January 2020, NP-01 is jointly developed by the Group and a PRC research institution. It is a new type of small molecule compound with independent intellectual property rights, and patents have been authorised in China, the United States and Europe. It is under type 1 new drug of chemical drug. Studies indicated that NP-01 shows excellent anti-tumor activity in various tumor animal models including gastric cancer, liver cancer, lung cancer and prostate cancer.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 10 November 2020

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.